| 1 |
34773566 | Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. | 2022 Mar |
1 |
| 2 |
34808283 | Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. | 2022 Feb 1 |
1 |
| 3 |
34897655 | Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population. | 2022 Mar |
2 |
| 4 |
33020924 | Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options? | 2021 Mar |
1 |
| 5 |
33305610 | Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. | 2021 Jan |
1 |
| 6 |
33544210 | Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. | 2021 May |
1 |
| 7 |
33587160 | Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines. | 2021 Apr |
1 |
| 8 |
33620159 | Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. | 2021 Jul |
1 |
| 9 |
33877893 | DPYD c.1905 + 1G>A Promotes Fluoropyrimidine-Induced Anemia, a Prognostic Factor in Disease-Free Survival, in Colorectal Cancer. | 2021 Apr |
2 |
| 10 |
34442436 | DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. | 2021 Aug 13 |
1 |
| 11 |
34484488 | DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment. | 2021 |
2 |
| 12 |
34650886 | Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable? | 2021 Sep |
1 |
| 13 |
34959317 | Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study. | 2021 Nov 29 |
3 |
| 14 |
32625092 | Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. | 2020 |
3 |
| 15 |
32899374 | A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature. | 2020 Sep 3 |
3 |
| 16 |
33197222 | All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. | 2020 Dec |
1 |
| 17 |
33235483 | Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments. | 2020 |
2 |
| 18 |
33280607 | Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms. | 2020 Dec 6 |
1 |
| 19 |
30349988 | Dihydropyrimidine Dehydrogenase Deficiency: Homozygosity for an Extremely Rare Variant in DPYD due to Uniparental Isodisomy of Chromosome 1. | 2019 |
1 |
| 20 |
30723313 | DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. | 2019 Dec |
3 |
| 21 |
30915274 | Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. | 2019 |
2 |
| 22 |
31155283 | Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. | 2019 Jun 6 |
2 |
| 23 |
31160238 | The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis. | 2019 Sep |
1 |
| 24 |
29152729 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. | 2018 Feb |
2 |
| 25 |
29998006 | Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. | 2018 Jun |
4 |
| 26 |
30087856 | A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening. | 2018 |
1 |
| 27 |
30348537 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. | 2018 Nov |
1 |
| 28 |
30349384 | Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. | 2018 |
1 |
| 29 |
30487465 | Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. | 2018 Nov 28 |
1 |
| 30 |
28024938 | Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. | 2017 Mar |
1 |
| 31 |
28347776 | Identification of new SNPs associated with severe toxicity to capecitabine. | 2017 Jun |
1 |
| 32 |
28427087 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. | 2017 May 23 |
1 |
| 33 |
28693254 | Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1. | 2017 Jul |
2 |
| 34 |
29045513 | DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. | 2017 Dec 1 |
4 |
| 35 |
29045550 | DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time? | 2017 Dec 1 |
1 |
| 36 |
29065426 | Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. | 2017 Oct 24 |
2 |
| 37 |
29340111 | Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy. | 2017 Dec 19 |
7 |
| 38 |
26801900 | Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations. | 2016 Jan 22 |
1 |
| 39 |
27181275 | Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients. | 2016 May |
1 |
| 40 |
27248859 | Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. | 2016 Jun |
1 |
| 41 |
27544765 | Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. | 2016 Oct |
1 |
| 42 |
27569869 | The role of pharmacogenetics in capecitabine efficacy and toxicity. | 2016 Nov |
1 |
| 43 |
27589829 | Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? | 2016 Nov |
1 |
| 44 |
25782327 | DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. | 2015 Sep |
1 |
| 45 |
25906475 | Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. | 2015 Apr 21 |
2 |
| 46 |
26099996 | Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. | 2015 Dec 15 |
2 |
| 47 |
26265346 | Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. | 2015 |
2 |
| 48 |
26330892 | Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. | 2015 |
3 |
| 49 |
26603945 | Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. | 2015 Dec |
1 |
| 50 |
29764069 | Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. | 2014 May |
1 |